Monday, May 5, 2025 5/5/2025

Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women

Award Number: R44AI143022
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women - HPV is the United States’ most prevalent sexually transmitted infection and the high-risk subtypes are of significant public health interest given that high-risk HPV (HR-HPV) infections have been conclusively linked to the development of certain cancers. Cervical intraepithelial neoplasias (CIN), caused by persistent HR-HPV infection, are categorized by grade, with high grades 2 and 3 being considered precancerous and grade 4, carcinoma in situ. While there are an estimated 250,000 to 1 million women diagnosed with CIN annually in the U.S., there are no minimally invasive therapies with direct antiviral activity for the treatment of CIN and excisional procedures are often associated with pain, fertility issues and recurrence. Despite the success of the prophylactic HPV vaccines, the incidence of HPV-induced cancer is steadily increasing, due to (a) the inability of the vaccine to cure preexisting infections; (b) a great majority of adolescent populations is not vaccinated; and (c) high rate of population growth. Novan’s platform technology enables the delivery of nitric oxide in a solid form, on demand and in localized formulations. Novan’s nitric oxide (NO)-releasing drug candidates have demonstrated the ability to inhibit papillomavirus amplification and replication in nonclinical models, as well safety and efficacy in a Phase 2 trial of external genital warts. The goal of this Fast-Track research plan is to develop a new formulation of a nitric oxide-releasing gel that can be self-administered by the patient, intravaginally, as a treatment for cervical HPV infections in women. If successful, such an approach may be instrumental in reducing the number of locally destructive surgical procedures in the U.S. and, ultimately, cervical cancers attributable to HPV. The Phase I portion of this research proposal is designed to formulate a stable gel formulation suitable for intravaginal administration and ensure the NO release profiles of the gel replicate profiles previously demonstrated to have antiviral effects. Go-no go criteria to transition from Phase I to Phase II is minimum stability of the formulation intended for clinical use in the U.S. (25˚C for 12 weeks) and an NO release profile that matches the high C-max and short half-life release profile previously demonstrated to have antiviral activity when delivered topically. The Phase II portion is designed to assess the gel formulation’s 1) in vitro toxicology: tumor promotion capabilities and effect on vaginal flora; 2) in vivo toxicology: safety, tolerability and toxicokinetics following application to mucosal surfaces via intravaginal administration in a 7-day pilot and a GLP 28-day repeat-dose toxicology study in rabbits necessary to submit an Investigational New Drug (IND) application; 3) pharmacology – ability to reduce vaginal papillomavirus infections and regress cervical neoplasias in a mouse model; and, 4) virology: evaluation of NO’s antiviral activity and mechanism of action against HPV-16 infected cells. The body of this work constitutes the foundational nonclinical studies necessary to submit an Investigational New Drug (IND) application to the FDA.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$656,173 )
2024	2023	NOVAN INC	4020 STIRRUP CREEK DR	DURHAM	NC	27703	DURHAM	USA	Allergy and Infectious Diseases Research	002	4	9/5/2024	NON-COMPETING CONTINUATION	-$1
2024	2021	NOVAN INC	4020 STIRRUP CREEK DR	DURHAM	NC	27703	DURHAM	USA	Allergy and Infectious Diseases Research	001	3	9/5/2024	NON-COMPETING CONTINUATION	-$126,370
2024	2020	NOVAN INC	4020 STIRRUP CREEK DR	DURHAM	NC	27703	DURHAM	USA	Allergy and Infectious Diseases Research	000	2	9/5/2024	EXTENSION WITH OR WITHOUT FUNDS	-$529,802
														Subtotal = -$656,173

Issue Date FY: 2023 ( Subtotal = $1 )
2023	2023	NOVAN, INC.	4020 STIRRUP CREEK DR STE 110	DURHAM	NC	27703	DURHAM	USA	Allergy and Infectious Diseases Research	002	4	4/19/2023	NON-COMPETING CONTINUATION	$1
2023	2020	NOVAN INC	4020 STIRRUP CREEK DR	DURHAM	NC	27703	DURHAM	USA	Allergy and Infectious Diseases Research	001	2	4/7/2023	EXTENSION WITH OR WITHOUT FUNDS	-$110,781
2023	2019	NOVAN INC	4020 STIRRUP CREEK DR	DURHAM	NC	27703	DURHAM	USA	Allergy and Infectious Diseases Research	000	1	4/7/2023	NEW	$110,781
														Subtotal = $1

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	NOVAN, INC.	4020 STIRRUP CREEK DR STE 110	DURHAM	NC	27703	DURHAM	USA	Allergy and Infectious Diseases Research	000	3	5/24/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $126,370 )
2021	2021	NOVAN, INC.	4105 HOPSON RD	MORRISVILLE	NC	27560	WAKE	USA	Allergy and Infectious Diseases Research	000	3	4/8/2021	NON-COMPETING CONTINUATION	$126,370
2021	2020	NOVAN, INC.	4020 STIRRUP CREEK DR STE 110	DURHAM	NC	27703	DURHAM	USA	Allergy and Infectious Diseases Research	002	2	6/5/2021	EXTENSION WITH OR WITHOUT FUNDS	$110,781
2021	2019	NOVAN, INC.	4020 STIRRUP CREEK DR STE 110	DURHAM	NC	27703	DURHAM	USA	Allergy and Infectious Diseases Research	001	1	6/5/2021	NEW	-$110,781
														Subtotal = $126,370

Issue Date FY: 2020 ( Subtotal = $997,413 )
2020	2020	NOVAN, INC.	4105 HOPSON RD	MORRISVILLE	NC	27560	WAKE	USA	Allergy and Infectious Diseases Research	000	2	2/18/2020	EXTENSION WITH OR WITHOUT FUNDS	$997,413
														Subtotal = $997,413

Issue Date FY: 2019 ( Subtotal = $223,131 )
2019	2019	NOVAN, INC.	4105 HOPSON RD	MORRISVILLE	NC	27560	WAKE	USA	Allergy and Infectious Diseases Research	000	1	8/12/2019	NEW	$223,131
														Subtotal = $223,131

Grand Total All Awards = $690,742

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women

Award Number: R44AI143022

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer